Background: Based on the results of phase III trial, @entity24986 was approved by European Medicines Agency in 2010 as second line treatment of advanced @entity5 in @entity1 with good performance status (ECOG 0-1). The objective of this prospective observational study was to assess @entity24986 treatment of advanced @entity5 @entity1 in terms of progression free survival and overall survival, and to evaluate @entity24986 @entity137 . @entity1 and Methods: From April 2011 to June 2014 a total of 16 @entity1 (100%) with advanced @entity5 were treated with @entity24986 . The median age was 62 years (range 43-80) and the median Karnofsky index was 90% (range 80-100%). Thirteen @entity1 (81.25%) had @entity150 , two @entity1 (12.50%) suffered from @entity1698 , and one @entity1 (6.25%) had @entity5 of unknown origin (histology was obtained from liver @entity3 ). Histologically, all the lesions were grade 3 @entity5 (100%). The number of metastatic sites ranged from 1-4 (median 3). Results: The effect of treatment was evaluated in accord with RECIST: two @entity1 (12.50%) obtained partial remission, three (18.75%) stabilization, eight @entity1 (50.00%) progressed, and treatment was suspended in one case at @entity1 request. @entity24986 @entity137 grade 3-4 included @entity1398 in six @entity1 (37.50%), @entity1431 in four @entity1 (25.00%), @entity417 in one @entity1 (6.25%), @entity1142 in three @entity1 (18.75%), and @entity1398 in one @entity1 (6.25%). Median overall survival was 5.2 months (95% CI 3.4-8.8) and median progressionfree survival was 2.3 months (95% CI 2.1-3.2). Conclusion: This study summarizes the first Slovak experience with @entity24986 therapy. Our data confirmed the efficacy of @entity24986 and its acceptable @entity137 in the treatment of @entity1 with advanced @entity5 previously treated with a platinumbased regimen.Key words: advanced @entity5 - @entity24986 - progressionfree survival - overall survival - side effects.

The First Slovak Experience with Secondline XXXX in Advanced Urothelial Carcinomas.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity24986 :: ('MESH:C111217', 'Chemical') :: ['vinflunine', 'Vinflunine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'urothelial cancer'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity150 :: ('MESH:D001749', 'Disease') :: ['urothelial bladder cancers'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1698 :: ('MESH:D014516', 'Disease') :: ['urothelial cancers of ureter'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']
@entity24986 :: (MESH:C111217,Chemical) :: ['Vinflunine']
